基线血清睾酮对激素初治晚期前列腺癌雄激素剥夺治疗结局的影响
该研究基于两项前瞻性随机3b期试验的汇总数据,事后分析838例接受持续雄激素剥夺治疗的激素初治晚期前列腺癌患者,评估基线血清睾酮的预后价值。结果显示基线睾酮低于250 ng/dl与更差的总生存和无进展生存显著相关,但至PSA进展时间无显著差异。
要点
- 基线睾酮低于250 ng/dl者总生存(HR 2.24)和无进展生存(HR 1.57)更差。
- 基线睾酮对至PSA进展时间无显著影响(HR 1.37;p=0.2)。
- 低基线睾酮组与正常组的关键肿瘤特征可比。
核心结论
- 较低的基线血清睾酮与激素初治晚期前列腺癌患者持续药物去势后更差的研究生存终点显著相关。
研究设计与样本
- 汇总两项大型前瞻性随机平行组3b期试验(NCT00295750全球;NCT00928434美国)进行事后分析,纳入838例接受持续雄激素剥夺治疗(激动剂或拮抗剂)且随访1年的激素初治晚期前列腺癌患者。
主要发现
- 意向治疗分析中,838例符合条件男性中138例(16.5%)基线血清睾酮低于250 ng/dl。
- 低与正常基线睾酮队列的关键癌症特征可比:Gleason评分7-10分别占55%与58%,分期和PSA≥20 ng/ml类别各占38%。
- 基线血清睾酮最低四分位切点值为≤282 ng/dl(206例患者)。
- 多变量分析显示基线血清睾酮对所有生存终点均有显著影响。
- 按饱和模型低切点<250 ng/dl,总生存(HR 2.24;p<0.02)和无进展生存(HR 1.57;p<0.02)仍显著,但至PSA进展时间不显著(HR 1.37;p=0.2)。
临床怎么用
- 在接受持续雄激素剥夺治疗的激素初治晚期前列腺癌患者中,可考虑基线血清睾酮水平用于预后分层。
- 未来需精心设计研究比较持续雄激素剥夺治疗(当前金标准)与更新替代方案,以优化个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study baseline serum testosterone's prognostic value in hormone naïve advanced prostate cancer patients receiving continuous androgen deprivation therapy. MATERIALS AND METHODS: The study population undergoing continuous androgen deprivation therapy (agonist or antagonist) with 1-year followup was pooled for post-hoc analysis from 2 large prospective, randomized, parallel arm phase 3b trials (NCT00295750-Global; NCT00928434-USA). Survival end points were evaluated for baseline serum testosterone effect as a continuous variable and compared for low (less than 250 ng/dl) vs normal (250 ng/dl or greater) groups based on the saturation model, using Kaplan-Meier survival estimates, log rank test, and Cox proportional hazards regression models incorporating established clinically important baseline factors. RESULTS: On intention to treat analysis 138 (16.5%) of 838 eligible men had baseline serum testosterone less than 250 ng/dl. Key cancer characteristics for low vs normal baseline serum testosterone cohorts were comparable; Gleason sum 7-10 (55% vs 58%), stage and prostate specific antigen 20 ng/ml or greater categories (38% each). The lowest baseline serum testosterone quartile cutoff value was 282 ng/dl or less (206 patients). Multivariable analysis showed a significant baseline serum testosterone effect for all survival end points. For the saturation model low cutoff less than 250 ng/dl, significance remained for overall (HR 2.24; p <0.02) and progression-free survival (HR 1.57; p <0.02), but not for time to prostate specific antigen progression (HR 1.37; p=0.2). CONCLUSIONS: Lower baseline serum testosterone was significantly associated with worse study survival end points in hormone naïve advanced prostate cancer patients undergoing continuous medical castration. Future well-designed studies should compare continuous androgen deprivation therapy (the current gold standard) with newer alternatives to optimize individualized management in these men.
引用
- Patel A. Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer? J Urol. 2020. PMID: 33035140. doi:10.1097/JU.0000000000001413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。